poisar

Stocks · News reference

Ruanyun Edai Technology Expects FY27 H1 Revenue Range ~$9.3M - $9.5M; FY26 H1 Revenue Expected In Range Of ~$8.M - $9.1M

Benzinga Newsdesk

Ruanyun Edai Technology Inc. (NASDAQ:RYET) ("Ruanyun" or the "Company") today announced that it expects preliminary unaudited revenue in the range of approximately US$9.3 million to US$9.5 million

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RYET
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

    Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.

    RYETBGLC